ALCON
15.12.2021 17:27:08 CET | Business Wire | Press release
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, continues its successful rollout of PRECISION1TM . The spherical lens is now available in key markets throughout Latin America and Asia, and PRECISION1 for Astigmatism is available in markets throughout Europe. PRECISION1 for Astigmatism and PRECISION1 sphere are also available throughout North America.
PRECISION1 contact lenses are designed to address the common reasons why 20% of new wearers drop out in the first three weeks: poor vision, poor comfort and handling issues.3 The lenses provide precise vision, long-lasting comfort and ease of handling to allow new wearers,1 especially those with long busy days, an exceptional lens-wearing experience.
Inspired from the water gradient lens material in DAILIES TOTAL1® , PRECISION1 is the first-and-only contact lens with Alcon’s proprietary SMARTSURFACE® Technology. This features a permanent, micro-thin, high-performance layer of moisture at the lens surface that helps support a stable tear film.4
A stable tear film is vital to visual performance and comfort, especially for contact lens wearers.5
“Reinforcing our mission to help people see brilliantly, we are proud of the PRECISION1 contact lens launch, designed for people with an on-the-go lifestyle, in many markets across the globe,” said Antoine Delgrange, Alcon Vice President for Vision Care International Marketing. “We understand the consumer journey can be challenging; so, as an added benefit, we are offering the opportunity for our customers to provide their new lens wearers with an exclusive activation program to make their introduction to contact lenses easy and enjoyable. The program includes resources to increase consumer confidence with their new lenses.”
“I think of PRECISION1 as the contact lens of the future. It’s so comfortable to wear and easy to fit that the wearing experience amazes my patients,” said Dr. Teodoro Tarud, optician and owner of Centro Óptico de la Costa, Columbia.*
The launch of PRECISION1 for Astigmatism provides a significant opportunity to attract new contact lens wearers. Studies show that 41% of patients have astigmatism that needs correction,6 but only 10% wear toric contact lenses.7 "Our patients love the comfort of PRECISION1! This is the best launch I have ever seen. We can fit more patient types now that toric and minus lenses are available," said Fiona Kavanagh, owner and optician at Jennings Opticians, Ireland.**
“We are committed to providing eye care professionals (ECPs) with a comprehensive portfolio of lens-wearing options based on the specific needs of their patients,” said Cheryl Donnelly, International Head of Professional Affairs at Alcon. “Now, with PRECISION1 and PRECISION1 for Astigmatism, ECPs and optical retailers can offer more lens wearers a next-generation contact lens with exceptional all-day performance.”
For more information, visit PRECISION1® One-Day Contact Lenses | PRECISION1® (myalcon.com)
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.
Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com .
* Teodoro Tarud is a paid Alcon consultant.
** Fiona Kavanagh is a paid Alcon consultant.
References
- Grant T, Tang A. A Survey of contact lens wearers and eye care professionals on satisfaction with a new smartsurface silicone hydrogel daily disposable contact lens. Clin Optom 2020;12:9–15.
- In a clinical study, wherein subjects were fitted with PRECISION1 for Astigmatism contact lenses (N=78 eyes); Alcon data on file, 2020.
- Sulley A, Young G, Hunt C, et al. Retention rates in new contact lens wearers. Eye & Contact Lens. 2018;44:S273-S282.
- In vitro analysis of verofilcon A contact lenses for surface properties; Alcon data on file 2019.
- Craig JP, Willcox MDP, Argueso P, et al. The TFOS international workshop on contact lens discomfort: Report of the contact lens interactions with tear film subcommittee. Invest Ophthalmol Vis Sci. 2013; 54:TFOS123-TFOS156.
- Luensmann D, Schaeffer J, Rumney N, et al. Spectacle prescriptions review to determine prevalence of ametropia and coverage of frequent replacement soft toric contact lenses. Contact Lens and Anterior Eye ; 2018; 41 (5); 412-420.
- Multi-Sponsor Surveys 2014 Gallup target market report.
Connect with us on
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
